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Photodynamic therapy (PDT) is an emerging treatment modality that involves the combined action of photosensitizers
(PSs) and light for treatment of solid tumor and other diseases. Although this therapeutic method has been considered
as an alternative to classical cancer treatments, clinical PDT requires further advances in selectivity and therapeutic
efficacy to overcome numerous shortages related to conventional PDT. In this regard, great efforts have been devoted
to the development of polymeric nanocarrier-encapsulated PSs for targeted PDT, aiming at improvement of water
solubility and tumor-specificity of hydrophobic PSs. Here, we discuss the general concepts and considerations of
polymeric nanocarriers for efficient delivery of PSs. In recent, the amphiphilic PS-polymer conjugate-based self-quenchable
nanoparticles and PS-polymer-conjugate/quencher nanocomplexes have emerged as an attractive delivery platform for
efficient and reliable PDT. They can incorporate and deliver the PS in a photodynamically inactive state but demonstrate
cytotoxic effects by tumor environment-sensitive activation mechanisms, so that the photodynamic cancer treatment
can achieve maximum target specificity. Here, we report the recent achievements on the development of activatable
PS formulations based on PS-polymer conjugates.
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Photodynamic therapy (PDT), a light-activated chemo-
therapeutic treatment, has emerged as an innovative
clinical modality for tumors and nononcological diseases
[1,2]. This modality is based on the selective retention of
a previously administrated photosensitizing molecule in
a target site and a measured light dose of appropriate
wavelength is then used to irradiate the target tissue. Upon
light irradiation, the photosensitizing molecule interacts
with molecular oxygen to generate various reactive oxygen
species to damage target cells via apoptosis and necrosis
[2,3]. PDT offers several advantages over conventional
therapies for malignant diseases [4-6]. For example, PDT
is a minimally invasive method that destroy target cells
without surgical risks, serious damages, and systemic
complications. Since PSs are typically harmless without
light, tumor site treatment can be precisely targeted by
selective illumination, thus, PDT is highly selective and
targeted in action. PDT can be applied repeatedly without
initiating resistance or exceeding total dose limitation (as* Correspondence: khuh@cnu.ac.kr
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unless otherwise stated.associated with radiotherapy). Over the past decade, PDT
is gradually becoming a more widely used clinical tech-
nique and has received regulatory approval for treatment
of a number of solid tumors [7], such as lung [8], bladder
[9], head and neck [10], ovarian [11], prostate [12], skin
[13] and bone carcinomas [14].
The photosensitizing molecules, named as photosensi-
tizers (PSs), function as catalysts when they absorb visible
light and convert molecular oxygen to a range of highly
reactive oxygen species (ROS) (singlet oxygen and free
radicals, such as OH−, O2
2− and O2
−). The detailed mech-
anism of action of PDT using PS is illustrated as shown in
Figure 1 [7,15]. Briefly, PS has a stable electronic configur-
ation with a singlet state in their lowest or ground state
energy level (PS0). Upon activation, the PS in its ground
state absorbs a photon and is promoted into an excited
singlet state (1PS*). The excited singlet state can relax back
to ground state by emitting a fluorescent photon or can
convert to the triplet state (3PS*) via intersystem crossing
which involves a change in the spin of an electron. This
triplet state is a photoactive state, which can interact with
molecular oxygen and produce reactive oxygen species
by undergoing two main reactions, Type I and Type IItd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Mechanism of PDT cytotoxicity: photophysical and photochemical reactions represented by modified Jablonski diagram.
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to various receptor molecules, producing free radicals
or superoxide ions resulting from hydrogen or electron
transfer. Type II reaction leads to produce the electron-
ically excited and highly reactive state of oxygen known
as singlet oxygen. In PDT, Type II processes are most
relevant, and the generation of singlet oxygen is respon-
sible for the irreversible damage of tumor cells [16]. In
addition to directly killing tumor cells through production
of ROS under light irradiation [17], PDT also can damage
the tumor-associated vasculature leading to tumor infarc-
tion [18], and can activate the immune response against
tumor cells [19,20].
In a PDT process, PSs are critical to the successful
eradiation of malignant cells. An ideal PS should meet
several crucial requirements [21]: (i) identified purity
and composition; (ii) minimal dark toxicity; (iii) photo-
stability; (iv) strong absorbance in a near-IR spectrum
range with high extinction molar coefficient; (v) water
solubility; (vi) tumor site target specificity; (vii) adequate
clearance rate from the body. The first generation PS
refers to Hematoporphyrin (Hp) and Photofrin® (hema-
toporphyrin derivative, HpD) [22]; and, Photofrin is
the first PDT agent approved for clinical use. It has
been considered as a therapy against various cancers,
such as lung, esophageal bladder, brain, breast, and
early-stage cervical cancer. However, although Photo-
frin has demonstrated significant therapeutic effects, it
still suffers from several drawbacks: first, Photofrin is a
complex and undefined mixture of dimeric and oligomeric
compounds having poor tissue penetration due to its rela-
tively weak absorbance in the red region of the spectrum;
second, it has a poor selectivity in terms of target tissue/
healthy tissue ratios; third, it has a low molar extinction
coefficient that requires use high doses of Photofrin and
light for adequate tumor eradication; forth, it readily accu-
mulate and stay in skin for a longtime, causing long-
lasting cutaneous photosensitivity [23]. To address these
problems, a wide variety of second generation PSs, such
as porphyrin derivatives [24,25], phthalocyanines [26-28],
and chlorins [29,30], have been developed. Comparing tothe first generation, they have the advantage of being pure
and well characterized; they can effectively generate sing-
let oxygen and have absorption maxima at wavelength
longer than 630 nm, at which light penetration in tissue is
enhanced; their relative high selectivity for malignant sites
and fast elimination from the body leads to a reduced skin
photosensitivity [22].
Although second generation PSs have addressed several
problems with first generation PSs, they still face the chal-
lenges associated with the PS delivery [31]. Most existing
second generation PSs are aromatic and hydrophobic in
nature with poor or limited solubility in water and hence
difficult to be intravenously administrated. Even in the
case of water-soluble PSs, the poor accumulation se-
lectivity at malignant sites makes them far from clin-
ical applications. Formulating hydrophobic PSs using
lipidic (e.g. Cremophor) or organic (e.g. propylene glycol)
excipients is reasonable for topical or local administration,
but can cause unpredictable biodistribution, toxicity, and
hypersensitivity if administrated intravenously [15]. The
unpredictable biodistribution can lead to a high plasma
retention and unexpected accumulation of PSs in healthy
tissues like skin, which often results in accidental damage
on blood vessels or non-disease tissues when the optical
equipment applied, and/or skin photosensitivity when the
patients expose to the sunlight or strong indoor lights. In
addition, as for excipients like Cremophor, the issues with
allergy, hypersensitivity reactions, and nephrotoxicity have
been often reported [32,33]. Therefore, a challenge in
PDT for treatment of malignant diseases is to design a safe
and tumor-specific carrier platform for systemic delivery
of PSs.
To date, a variety of macromolecular nanocarrier plat-
forms such as liposomes [34-36], polymeric nanoparticles
[37-41], and micelles [42-45] have been investigated for
their potential application in PS delivery (Figure 2), which
can provide an effective solution to overcome the short-
ages of current PSs associated with intravenous adminis-
tration and selective delivery of the PS to the tumor sites.
Beneficial effects of these nanocarriers lie in their excellent
colloid dispersity in water that enables solubilization of
Figure 2 A schematic diagram of PS-encapsulated polymeric nanocarriers: (A) liposome, (B) polymeric nanoparticle, and (C)
polymeric micelle.
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hanced accumulation at tumor sites through enhanced
permeability and retention (EPR) effect (Figure 3) [46,47].
Generally, PS can be encapsulated using these carriers by
both physical methods using hydrophobic or electrostatic
interactions between PS and polymers and chemical
methods using various conjugation reactions of PSs to
polymers and nanoparticles. The general concepts and
considerations of polymeric nanocarriers for delivery of
PS will be resumed. In addition to the delivery strategies to
modulate the pharmaceutical features and biodistribution
of PS, a series of amphiphilic PS-polymer conjugate-based
self-quenchable nanoparticles [48-52] and PS-polymer-
conjugate/quencher nanocomplexes [53-55] have been
recently developed. A common characteristic feature of
these platforms is that they can incorporate and deliver
the PS in a photodynamically inactive state and create
active forms and produce cytotoxic effects only at the
tumor site. Since the direct tumor cell destruction es-
sentially depends on the in situ generation of cytotoxicFigure 3 Schematic presentation of passive targeted PDT through EP
selectively through the “leaky” vasculature surrounding the tumors.singlet oxygen, a controllable singlet oxygen production
with high selectivity and localization would lead to more
efficient and reliable PDT, thereby, significantly reducing
the associated side effects in PDT, such as skin photo-
sensitivity. In a second part, we will describe the strategies
that involved in construction of activatable PS formula-
tions based on polymer-PS conjugates and their applica-
tions in tumor site-specific PDT.
Review
Polymeric nanocarriers for delivery of hydrophobic
photosensitizers
To enhance the water solubility and increase the specific
accumulation of PSs at the target site, a generally used
strategy is encapsulation of the PSs to macromolecular
nano-constructs. In this respect, liposomes [34-36],
polymeric micelles [42-45], and polymeric nanoparti-
cles [37-41] have been extensively studied for serving
as PS carriers in PDT. A common characteristic feature
of above mentioned platforms is that they demonstrateR effect. PSs encapsulated into nanocarriers can reach tumors
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microvascular permeability and impaired lymphatic drain-
age in the tumor tissue, a phenomenon which Maeda
et al. termed the EPR effect [56,57]. Therefore, systemic
PS delivery based on polymeric nanocarrier systems can
provide an effective way to not only enhance the water
solubility but also modulate the biodistribution profile of
hydrophobic PSs and thus facilitating intravenous admin-
istration and selective delivery of PS to target tissues.
Liposomes
Extensive research has been carried out to use liposomes,
bilayered phospholipid vesicles, to formulate the hydro-
philic or hydrophobic PSs owing to their simple archetypal
structures, controllable sizes, and convenient preparation
procedure. The hydrophobic PS, such as porphyrin [58]
and phthalocyanine derivatives [59], can be dissolved in
the phospholipid bilayer region, while the water soluble
molecules, such as the prodrug aminolevulinic acid [60],
can be encapsulated in the inner core of liposomes. The
advantageous of liposome carriers for PS delivery have
been described by a number of investigations, which have
shown their beneficial effects over other formulations such
as simple aqueous dispersions of the PSs. For example,
Richter et al. have studied biodistribution and clearance of
benzoporphyrin derivative monoacid ring A (BPD-MA)
encapsulated into a unilamellar dipalmitoylphosphatidyl-
choline (DPPC) liposome in comparison to the drug dis-
solved in a dimethyl sulfoxide solution and a PBS solution
[61]. The in vivo study in M1 rhabdomyosarcoma-bearing
mice has shown that the maximum concentration of lipo-
some formulation in tumor tissue was obtained 15 min
post-injection against 3 h for both aqueous formulations.
Under light treatment, the liposomal formulation showed
significantly more therapeutic efficacy than both aqueous
formulations. However, conventional liposomes (unmodi-
fied multilamellar or unilamellar liposomes composed of
phospholipid) are sometimes suffered from short plasma
half-life, which is insufficient time for tumor cell uptake
given the rapid elimination by the reticuloendothelial
system (RES) and decomposition due to in-body lipid
exchange interactions [34]. In this regard, many ap-
proaches based on surface modifications of liposomes
were explored to produce the long-circulating lipo-
somes featuring substantially enhanced plasma stability.
For instance, inclusion of lipids with poly(ethylene gly-
col) (PEG)-head groups can stabilize the liposome and
increase its bioavailability by facilitating evasion of the
RES. PEGylated liposomes loaded with chlorin e6 ester
have been reported to enhance PDT efficiency compared
to the free PS in gastric cancer cell lines in vitro and
in vivo [62]. For the long-circulating liposomes, conjuga-
tion of the cancer cell targeting moieties, such as ligands,
antibodies, proteins and peptides, can effectively increasecancer cell targeting specificity and improve the cellular
uptake of liposomes [34,63].
Polymeric nanoparticles
As an alternative to liposomes, polymeric nanoparticles
have been considered as prospective delivery vehicles for
PS payloads in PDT. The particle size of polymeric
nanoparticles can be easily tailored in the nanometer
range by altering the polymer composition and manu-
facturing processes [64], which is an important factor
that enable the PS formulations to be delivered to tumor
site through EPR effect and prevent recognition by macro-
phages and proteins with prolonged circulation time in
the blood. In addition, by coating with “stealth” PEG, the
nanoparticles can efficiently avoid to be taken up by RES
after intravenous administration and consequently in-
creasing the blood circulation time [65,66]. Usually, the
hydrophobic PSs can be physically entrapped into nano-
particles by hydrophobic or electrostatic interactions
between PS and the polymer. Biodegradable polymers,
such as polyglycolide (PGA), polylatide (PLA), and their
copolymer poly(D,L-lactide-co-glycotide) (PLGA), have
been particularly utilized as matrix materials for PS
delivery [40,67]. The main advantages lie in their versa-
tility, physical robustness, and high drug loading. In
addition, their surface properties, morphologies, and
composition of polymer matrices can be easily optimized
to control the polymer degradation and drug release
kinetics for achieving controlled release of PS. As
reported by Allemann et al. [68], hexadecafluoro zinc
phthalocyanine, was formulated in PEG-coated PLA
nanoparticles by the salting out technique with a drug
loading of 0.61%. As tested in EMT-6 tumour-bearing
mice at a dose of 5 μmol/kg, the PS-loaded nanoparticles
caused tumor regression in 100% of mice compared to
only 60% with the Cremophor EL emulsion. The results
indicated that formulation in the biodegradable nano-
particle improved PDT response of the tumor as com-
pared to conventional Cremophor EL emulsion while
providing prolonged tumor sensitivity towards PDT. A
second generation PS, meso-tetra(hydroxyphenyl) porphy-
rin (p-THPP) was entrapped into sterile sub-150 nm
biodegradable nanoparticles based on three selected
polyesters PLGA (50:50 PLGA and 75:25 PLGA) and
poly(D,L-lactide) (PLA) using the emulsification-diffusion
technique [69,70]. The effect of copolymer composition
on particle size, drug loading efficiency, and PDT effect
has been investigated. A follow-up study was carried
out to assess the PDT efficacy of these p-THPP loaded
nanoparticles on EMT-6 mouse mammary tumor cells
as compared to free p-THPP. The relatively low drug
concentration and the short incubation times of nano-
particles with cells required to induce satisfactory
photodynamic damages demonstrated that p-THPP loaded
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the free drug.
Polymeric micelles
Polymeric micelles are macromolecular complexes formed
spontaneously when amphiphilic block or graft copoly-
mers are dispersed in aqueous solution above the critical
micelle concentration (CMC). The hydrophobic segments
of amphiphilic copolymer exhibit poor compatibility
with the aqueous phase and readily assemble to form a
core structure for incorporation of hydrophobic drugs.
The outer shell region made up by the hydrophilic
segments maintains a stabilizing interface between the
hydrophobic compartment and the aqueous environ-
ment, thus, allowing to solubilize the hydrophobic PSs.
In addition, formulating hydrophobic PSs with micelles
also could facilitate the control of the drug release in
specific site by diffusion, polymer degradation or micelle
dissociation mechanisms. Large variety of lipophilic
polymers can be used as core forming blocks, such as
poly(amino acids) and poly(esters) [71]. However, the
corona has almost exclusively been constituted from
PEG because of its high water solubility, biocompatibil-
ity, and nonfouling properties [72]. Usually, physical
incorporation of the hydrophobic PSs can be achieved
by various manufacturing processes, such as thin-film
hydration, dialysis, or oil-in-water emulsion methods,
which lies on the hydrophobic-hydrophobic interaction
between drugs and hydrophobic moieties of the copoly-
mer. In PDT, polymeric micelle has been extensively
investigated as an alternative platform for delivery of
hydrophobic PS and presents several advantages, such
as simple preparation, efficient drug loading without
chemical modification, and controlled release. Such mi-
celles also exhibit long blood-circulation times and tumor
selectivity based on the EPR effect, thus decreasing the
unfavorable biodistribution of hydrophobic PSs and
consequently reducing the adverse effects like skin
photosensitivity. Li et al. reported a formulation of PEG-
b-poly (caprolactone) (PEG-PCL) micelle incorporated
with hydrophobic protoporphyrin IX (PpIX) [73]. The
micelles have a high PpIX-loading efficiency of 82.4% and
a narrow size distribution with a mean diameter of 52 nm.
In comparison with the free drug, formulation of PpIX in
micelles enhanced the total intracellular accumulation of
the agent, and thereby markedly increased the photocyto-
toxicity of PpIX. Hence, the formulation of PpIX in block
copolymer micelles may allow the desired PDT efficiency
to be achieved at a reduced dose of drug and/or light.
The poly(2-ethyl-2-oxazoline)-b-PLA diblock copoly-
mer micelle was used to incorporate meta-tetra(hydro-
xyphenyl) chlorin (mTHPC) [74]. The m-THPC-loaded
micelles exhibited marked PDT effect in vivo, and the
therapeutic efficacy was similar to free drug. However,the m-THPC-loaded micelles had less skin phototoxic-
ity after an extended delivery time comparing with free
drug. The enhanced tumor specificity of a PS-loaded
polymeric micelle could improve therapeutic efficacy
while decreasing its adverse effects. Unfortunately, most
hydrophobic PSs incorporated into micelles easily form
aggregates due to their π-π interactions and hydrophobic
characteristics. Such aggregate formation may severely
decrease singlet oxygen generation due to the self-
quenching of the excited state. With this regard, incorp-
oration of unaggregated monomeric molecules of PSs
into polymeric micelles was considered to retain the
therapeutic efficacy of PS’s micellar formulation. Knop
et al. [75] has reported that the pheophorbide a (PhA)-
loaded PEG-PCL micelle with 20 nm in hydrodynamic
diameter, corresponding to approximately 200 mole-
cules of polymer and 4 molecules of monomeric PhA
per nano-object, was able to efficiently generate singlet
oxygen in the medium. In vitro tests on human cancerous
cells have revealed a ca. 2-fold enhanced photocytotoxicity
and cellular uptake compared to free PhA.
Indeed, polymeric micelles are attractive carriers for
improving PS delivery by enhancing aqueous solubility
and retaining the PS payload in the blood for an extended
period of time, thus allowing for sufficient EPR-mediated
accumulation in the pathological area. However, PS-
loaded micelles in blood circulation have been found to
present a risk of skin photosensitivity, which could lead to
damage of endothelial cells or neighboring blood-vessel
cells. In order to reduce unwanted photoactivity at
non-target sites, we have proposed a new concept for
PS-loaded micelles with the ability to prevent singlet
oxygen production during the post-treatment period
(Figure 4) [76]. As a proof-of-principle of our strategy,
PEG-PCL micelles co-loaded with PhA as the singlet
oxygen generator and β-carotene (CAR) as the singlet
oxygen scavenger were prepared. We observed that the
CAR scavenger in the PhA/CAR micelles significantly
diminished PhA-generated singlet oxygen through direct
singlet oxygen scavenging in a physiological condition.
However, tumor-cell-internalized PhA/CAR micelles ex-
hibited remarkable phototoxicity because of the termin-
ation of the scavenging reactions by the intracellular
disassembly of the micelle structure and the subsequent
drug release. These findings suggest that PhA/CAR mi-
celles could be a promising PDT agent with controllable
PDT activity for cancer treatment. Our approach, which
co-incorporates a singlet oxygen scavenger in combination
with PS into micelles, is an attactive strategy that could
permit more accurate PDT to minimize photodamage to
non-target tissues, blood cells, or healthy tissues, thus
making PDT a safer and more selective clinical technique.
While the polymeric micelle has been extensively
investigated as a prospective platform for delivery of
Figure 4 PEG-PCL micelles co-loaded with PhA as the singlet oxygen generator and CAR as the singlet oxygen scavenger for targeted
PDT. (A) Chemical structures of PEG-b-PCL copolymer, CAR, and PhA. (B) Co-incorporation of PhA and CAR into PEG-PCL micelle. (C) Schematic
presentation of photodynamic cancer therapy using PhA/CAR micelles: i. intravenous administration of drug-loaded micelles; ii. during blood
circulation, PhA/CAR micelles is expected to be safe with minimal photodamage to non-target tissues induced by CAR-mediated singlet oxygen
scavenging; iii. when the micelles were internalized by cancer cells, PhA and CAR molecules are released from the micelles and then become
spatially isolated, resulting in PhA-induced singlet oxygen production and photokilling activity; iv. tumor site restored to health after PDT.
Reproduced with permission from: [76].
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to delivery of a genetically encoded PS for photodynamic
cancer treatment [77]. Genetically encoded PS is a re-
cently reported optogenetic tool that enables local ROS
production mediated by a fluorescent protein [78]. The
unique feature of genetically encoded PS is that cancer
cells bear a gene encoding phototoxic protein and produce
protein in the adjusted cell compartment, consequently,
being expressed in tumor cells rather than administered
exogenously [79]. Therefore, the problems of associated
with nonspecific PS accumulation in normal tissues could
be addressed. Two fluorescent proteins having phototoxic
properties are currently known, namely KillerRed (KR)
and miniSOG (mini Singlet Oxygen Generator). KR is a
dimeric green fluorescence protein (GFP)-like protein that
can produce ROS by selective activation using a 585 nmof light [80]. Another phototoxic protein miniSOG is a
small monomeric flavoprotein that can be excited at
448 nm and produce singlet oxygen with a high yield
(0.47) [81]. However, for these fluorescence protein-based
PSs, the ROS generation process only affects cells that ex-
press proteins, otherwise the cells will remain intact when
they are prevented from uptake of the encoding thera-
peutic plasmids. In this respect, polymeric micelle could
be utilized to deliver the protein-based PSs for improving
the applicability of genetically encoded PS. In Muthiah’s
report [77], a quantum dot (QDot)-encapsulated poly(2-
hydroxyethyl aspartamide) grafted PEG and branched
polyethylenimine (PPP) polymeric micelle has been pre-
pared to deliver the KR plasmid to cancer cells. The
quantum dot, CdSe/ZnS, was used as a light harvesting
moiety that can facilitate the locally emission of green
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cytoplasm. Intracellular activation of PPP-QDot/KR mi-
celles using a blue light leads to efficient production of
ROS; therefore, morphology changes, reduced metabolic
activity, and apopotosis of PPP-QDot/KR-treated cancer
cells are observed. In addition, by targeting the uptake
of PPP-QDot/KR micelles to cancer cells, the cells can
be selectively destroyed without affecting normal cells
in terms of survival or proliferation. These findings sug-
gest that delivery of the KR using polymeric micelles
with multifunctional capacity can be an effective cancer
treatment strategy.
Activatable photosensitizer formulations based on
polymer-PS conjugates for tumor site-specific PDT
Based on the mechanism of action of PDT, the direct
photodamages on tumor cells highly depend on the in
situ generation of cytotoxic singlet oxygen that causes
the irreversible damages to pivotal biomacromolecules
and other cellular components. Implementation of a
controllable singlet oxygen generation with high select-
ivity and localization would lead to more reliable PDT
with minimial phototoxicity to normal cells and hence
enhanced efficacy for photodynamic cancer treatment.
Above mentioned polymer-based nanocarriers have
been considered as targeting platforms for PS delivery.
These carrier systems have been demonstrated to show
tumor-selective accumulation of PS due to the EPR
effect that may improve the therapeutic efficacy of PDT.
However, the EPR-based targeting strategies are usually
incapable to restrict the localization of PS activation,
which may be caused by the unexpected leakage of the
PSs during systemic circulation [82]. Therefore, the con-
trol of tumor site-specific singlet oxygen production may
be essential for avoiding associated side effects of PDT.
An activatable PS formulation is a more sophisticated
class for PS delivery, which can keep the photoactivity of
PS dormant during systemic circulation but demonstrate
phototoxicity only at the tumor site [83]. Generally,
activatable PSs can be constructed by chemically linking
PS with its activation controllers through stimuli-sensitive
or cleavable linkers. The linkers between the PS and its ac-
tivation controller can be specifically degraded by a variety
of physicochemical and biological stimuli that exist solely
or at very high levels in tumor sites, releasing PS in a
photo-active form. PDT with activatable PSs is a promis-
ing therapeutic option since it can directly kill cancer cells
with reduced side effects in non-target tissues [82-84].
However, current activatable PS formulations are often
constructed with a low-molecular-weight system, such as
PS-PS [85] or PS-quencher conjugate [86] system, which
may suffer rapid elimination from the body and may pos-
sess multiple drug resistances, resulting in a short plasma
half-life and low bioavailability. In order to address theseshortcomings, the activatable formulations based on
polymer-PS conjugates have been recently developed.
Self-quenchable nanoparticles [48-52] formed by self-
aggregation of PS-polymer amphiphilies and PS-polymer
conjugate/quencher nanocomplexes [53-55] have been
recently reported. These platforms not only possess the
common characteristic features of low-molecular-weight
activatable systems but also can be maintained stable in
the circulatory system for an extended time period due to
their appropriate size and surface properties, increasing
the possibility for selective accumulation at tumor site
through EPR effect.
Self-quenchable nanoparticles
Some active PDT agents have been based on energy
transfer between PSs by control of the aggregation/disag-
gregation (Figure 5). In this respect, PS-PS self-quenching
through fluorescence resonance energy transfer (FRET)
mechanism is the deactivation strategy involved in control
of the photoactivity of the PSs. FRET is a nonradiative and
distance-dependent energy transfer process that based on
the interaction between the electronic excited states of
two dye molecules in which excitation is transferred from
a donor molecule to an acceptor molecule [83]. In recent,
a variety of PS-polymer amphiphilies were synthesized for
development of self-quenchable nanoparticles (Figure 6)
[48-52]. When the hydrophobic PS molecules conjugated
to the hydrophilic backbone polymers with an appropriate
hydrophilic-hydrophobic balance, the amphiphilic nature
of such polymer-PS conjugates could allow them to read-
ily self-assemble to form nano-sized core-shell-structured
nanoparticles in aqueous conditions, resulting in π-π-
stacked self-aggregation among hydrophobic PS molecules
in the NPs. Under light exposure, PS molecule promotes
from its ground state to an excited singlet state, the neigh-
boring PS molecule, as a FRET acceptor, may act on this
excited singlet state before the PS enters its triplet state
through energy transfer, resulting in the interruption of in-
tersystem crossing. Thus, the pathway for singlet oxygen
generation is blocked. As the result of efficient self-
quenching, the desired characteristics of self-quenchable
nanoparticles can allow the PS molecules to remain pho-
todynamically inactive in the nanoparticulate formulation
during systemic circulation to inhibit harmful singlet oxy-
gen generation. In addition, the suppression can be rapidly
reversed by molecular stimuli or environment conditions
at the tumor site, which allows the PSs to restore the
photoactivity and consequently produce cytotoxic species
under light exposure.
In recent studies, natural polysaccharides have been
popularly used for the development of self-quenchable
nanoparticles due to their outstanding merits, such as
high water solubility, good biocompatibility, a wide
range of molecular weights, and an abundance of sources.
Figure 5 A schematic diagram of self-quenchable nanoparticles. The self-quenchable nanoparticles can incorporate and deliver the PS in a
photodynamically inactive state and create active forms and produce cytotoxic effects only at the tumor site.
Figure 6 Various of PS-polymer amphiphilies for preparation of self-quenchable nanoparticles: (A) acetylated hyaluronic acid-pheophorbide a
conjugate (Ac-HA-PhA) [48], (B) pheophorbide a/folate-pullulan conjugate (PFP) [49], (C) folate-heparin-pheophorbide a conjugate (FHP) [50],
(D) photoporphyrin IX-glycol chitosan conjugate (PpIX-GC) [82], (E) disulfide linked pheophorbide a-glycol chitosan conjugate (PhA-ss-GC) [51],
(F) biarmed bioreducible poly(ethylene glycol)-pheophorbide conjugate (PEG-(ss-PhA)2) [52].
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luronic acid-PhA (Ac-HA-PhA) conjugates were reported
[48]. The Ac-HA-PhA amphiphilic conjugates readily
formed 125 ~ 150 nm nanogels when degree of substitu-
tion of PhA molecules per glycosaminoglycan unit of
AC-HA varied from 0.31 to 0.08. The resulting nanogels
quenched both the PhA’s fluorescence and singlet oxygen
generation through a hydrophobic interaction between
PhA themselves. In tumor cells, the photoactivity of
Ac-HA-PhA nanogel could be restored, due to the
dequenching behavior induced by the enzymatic deg-
radation of polysaccharide backbone, thereby produ-
cing singlet oxygen to kill tumor cells under light
exposure. Another self-quenchable system based on
pullulan/folate-PhA (PFP) conjugates was reported by
the same group [49]. The enzyme-treated PFP self-
quenchable nanogel showed fluorescence and singlet
oxygen generation, which could not be observed in
PBS due to the self-quenching effect between PS moi-
eties. In the cell culture system, a dramatic increase in
photoactivity induced by disintegration via lysosomal
enzymes was observed. In addition, the PFP nanogel
exhibited significant phototoxicity to tumor cells, while its
cytotoxicity in darkness was negligible in the test range.
After subcutaneously injection of PFP nanogels into the
non-tumor-bearing Balb/C-nude mice, fluorescence did
not immediately appear but was detected after 30 min and
significantly increased for 12 h due to the dissociation and
degradation-induced dequenching of the nanogels. Our
group reported synthesis of heparin-PhA (HP) and folate-
heparin-PhA (FHP) conjugates for preparation of self-
quenchable nanoparticles for controllable PDT [50]. HP
and FHP conjugates could self-assemble in aqueous media
to form nano-sized particles with 130–170 nm in size.
They displayed a self-quenching effect in PBS, while the
generation of singlet oxygen dramatically increased in
DMF where they exist as dissociated forms. In tumor cells,
HP and FHP nanoparticles exhibited marked phototoxic-
ity and were minimally dark-toxic without light treatment.
Lee et al. has developed the protoporphyrin IX (PpIX)
conjugated glycol chitosan (GC) nanoparticles as a self-
quenchable system for PDT [87]. PpIX-GC nanoparticles
showed the self-quenching effect with no fluorescence
signal and phototoxicity under light exposure, which is
due to the compactly crystallized PpIX molecules in the
nanoparticles. The switchable photoacitivity of PpIX-
GC nanoparticles attributes to dequenchability induced
by disruption of the condensed nanoparticle structure
at the harsh intracellular condition. After intravenous
injection into HT-29 human colon adenocarcinoma
tumor-bearing mice, they were observed to rapidly and
significantly accumulate into the tumor tissue, and
displayed strong fluorescence signals and significant
therapeutic efficacy according to the effective in-bodydequenching properties. By using GC as backbone poly-
mer, we have reported cancer-cell specific PS nano-carrier
by synthesizing PhA conjugated GC with reducible disul-
fide bonds (PhA-ss-GC) [51]. In order to enable quicker
release kinetics and a more efficient activation mechanism
of the PSs in the tumor cells, such a bioreducible
nano-carrier system was especially interested, which
might maximize the cytosolic dose of active PSs to achieve
higher cytotoxicity, thereby enhancing the treatment
efficacy. The relative fast intracellular degradation rate
of PhA-ss-GC nanoparticles depends on that the thiol
responsive disulfide linkers in the nanoparticles should
be rapidly cleaved in the cytosol, as the concentrations
of glutathione (GSH) in the cytosol (approximately 2–
10 mM) are much higher than those in extracellular
fluids (approximately 2–20 μM) [88]. The photoactivity
of PhA-ss-GC nanoparticles in an aqueous environ-
ment was greatly suppressed by the self-quenching
effect, which enabled the nanoparticles to remain photo-
inactive and in a quenched state. However, after the can-
cer cell internalization, PhA-ss-GC nanoparticles rapidly
restored their photoactivity, which is the result of the
dissociation of the nanoparticular structure induced by
reductive cleavage of the disulfide linkers. Compared to
non-reducible PhA-GC nanoparticles with stable amide
linkages, PhA-ss-GC nanoparticles presenting higher
cytotoxicity with light treatment. In addition, the PhA-
ss-GC demonstrated tumor specific targeting behavior
through the EPR effect and enhanced tumor therapeutic
efficacy compared to free PhA in tumor-bearing mice.
The above mentioned self-quenchable photosensitizing
formulations basically have made up using natural polysac-
charides as backbone polymers, but these matrix-forming
materials have not been presently approved by Food and
Drug Administration (FDA) as safe excipients for antican-
cer drug delivery, therefore, the development of clinically
relevant formulations for controllable PDT is still a chal-
lenge. PEG is a nontoxic, nonimmunogenic, nonantigenic,
and water-soluble polymer that is approved by the FDA as
a safe excipient for ststemic delivery [65]. Utilizing PEG as
a backbone polymer may promote the strategy regarding
self-quenchable PS carrier system more close towards
practical clinical application. In recent, we developed a
bioreducible biarmed mPEG-(ss-PhA)2 conjugate for
cancer-cell specific photodynamic therapy [52]. PhA
molecules were chemically conjugated with biarmed
linkages at one end of the mPEG molecule via disulfide
bonds. As expected, the amphiphilic mPEG-(ss-PhA)2
conjugates readily self-assembled to form core/shell
nanoparticles in the aqueous media. We observed that
the photoactivity of mPEG-(ss-PhA)2 nanoparticles was
significantly suppressed in the physiological conditions be-
cause of their self-quenching properties. However, when
the NPs are internalized by cancer cells, the intracellular
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erates the dissociation of the nanoparticle structure and
causes the PhA molecules to restore their photoactivity.
The bioreducible activation mechanism of mPEG-(ss-
PhA)2 NPs in cancer cells can efficiently maximize the
cytosolic dose of active PSs to achieve high cytotoxicity
under light exposure, thereby enhancing the treatment
efficacy of photodynamic cancer treatment with reduced
side effects.
Polymer-PS conjugate/quencher nanocomplexes
Besides the self-quenching approach for control of the
photoactivity of PSs, the specific deactivation of polymer-
modified PSs can be achieved by PS-quencher complex-
ation strategy. Generally, this strategy involves in synthesis
of water-soluble PS-polymer conjugates, followed by bind-
ing to quencher molecules that act as FRET acceptors
through covalent or physical bond. A polymeric PS withFigure 7 Polyelectrolyte nanocomplex with controllable photoactivity p
an anionic polysaccharide quencher for PDT. (A) Chemical structure of cat
chlorine e6 conjugate (PEG-PEI-Ce6)) and anionic polysaccharide quencher (B
(B) Synthesis of opposite charged polyelectrolyte and facile preparation of nacontrollable photoactivity was prepared from a polyelec-
trolyte complex between cationic PEG-polyethylenimine-
chlorine e6 conjugate (PEG-PEI-Ce6) and anionic Black
Hole Quencher-3 chondroitin sulfate conjugate (BHQ-3-
CS) (Figure 7) [53]. BHQ-3 was used as dark-quenching
material that is able to deactivate the photoactivity of
PS by FRET-based photoquenching when it was close
neighbored with Ce6 in the nanoparticles. The nano-
particles clearly lost photoactivity by the intermolecu-
lar FRET effect in the aqueous phase. However, the
quenched photoactivity was restored by the enzymatic
degradation of BHQ-3-CS after esterase treatment. In
the cell culture system, the rapid cellular internaliza-
tion and the significant phototoxicity were observed.
Recently, we have reported a new GSH-responsive hybrid
nanoparticle, PhA-conjugated heparin/gold nanoparticle
(PhA-H/AuNP), for controllable PDT (Figure 8) [54]. A
thiolated water soluble polymeric PS, PhA-heparin, wasrepared by ionic interactions between a cationic polymeric PS and
ionic water soluble polymeric PS (poly(ethylene glycol)-polyethylenimine-
lack Hole Quencher-3 chondroitin sulfate conjugate (BHQ-3-CS)).
no-PS in the aqueous phase. Reproduced with permission from: [53].
Figure 8 Hybrid PhA-conjugated heparin/AuNP for cancer cell-specific PDT. (A) Schematic diagram of formation of hybrid pheophorbide
a/heparin-gold nanoparticle (PhA-H/AuNP) and GSH-mediated photoactivity: PhA becomes photoinactive when immobilized onto the AuNP
surface. When PhA-H/AuNPs are internalized by cancer cells, GSH can trigger the release of PhA-H from AuNPs by cleavage of the gold-thiol linkages,
causing the recovery of photoactivity of PS payloads. The activated PhA molecules can efficiently generate singlet oxygen to cause cancer cell
destruction. (B) And (C), GSH-mediated generation of fluorescence and singlet oxygen, respectively. Reproduced with permission from: [54].
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gold-thiol interaction. AuNP is a well-known quencher
for efficient energy transfer based on FRET mechanism
for excited dye molecules, which can quench the excited
energy of fluorochromes even at a distance of around
40 nm. In our study, AuNP was used not only as a nano-
carrier for loading the polymeric PS but also as a quencher
material for deactivation of the surface attached PS.
Furthermore, the release of PS payloads from the surface
of AuNP triggered by GSH-mediated ligand exchange re-
action can be expected to cause the effective dequenching
processes and thus recovery of the photoactivity. As the
result of quenching and dequenching behaviors of
PhA-H/AuNP, we observed that the photoactivity was
significantly suppressed in aqueous media, but instantan-
eously restored at the GSH-rich intracellular environment
to generate a strong fluorescence signal together with ac-
tive production of singlet oxygen species with light treat-
ment. In vitro cell tests revealed marked phototoxicity and
high intracellular uptake of PhA-H/AuNPs in contrast
with free PhA. The PhA-H/AuNPs also exhibited a pro-
longed circulation characteristic, enhanced tumor speci-
ficity, and improved photodynamic therapeutic efficacycompared with free PhA in A549 tumor-bearing mice. As
the follow up study, we further prepared a multifunctional
hybrid nanoparticle system with a core/shell-structured
magnetic Fe3O4/Au nanoparticle and a PhA-heparin
surface layer as an activatable platform for PDT [55].
The novelty of the PhA-H/Fe3O4/Au hybrid nanoparti-
cle lies in the fact of that unique and inherent surface
property of gold shell: (i) suppression of photoactivity
caused by the quenchability of the gold shell and (ii)
restoration of photoactivity caused by GSH-mediated
dequenchability of the surface-conjugated PS mole-
cules. In addition, in vitro MRI studies reveal that the
PhA-H/Fe3O4/Au nanoparticles could potentially serve
as MRI contrast agents in cancer diagnosis and may be
used to monitor the photodynamic treatment response
used to accurately guide light irradiation.
In a summary, precise control of intracellular site of
singlet oxygen production may be essential for efficient
tumor cell destruction and reduce the side effect of PDT.
Polymer-based activitable PSs are attractive formulations
that may enhance therapeutic effect with reduced side
effects. They have several advantages for efficient PS
delivery: (1) the solubilization of hydrophobic PSs, (2)
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tumor selectivity, (4) tumor site-specific generation of
cytotoxic species under light exposure.
Conclusion
PDT has emerged as one of the important therapeutic
options in management of cancer. However, there are
several shortcomings in the application of conventional
PS-based PDT to the treatment of solid tumors. Most
clinical applied PSs have limitations such as poor water
solubility and low selectivity between tumor and normal
tissues for clinical use. Physical encapsulation of PSs into
polymer nanocarriers could overcome or reduce inherent
limitations that the conventional PS formulations have.
PS-encapsulated polymeric nanocarriers may act as a
stable formulation for hydrophobic PS under physiological
conditions and have an appropriate size for prolonged
blood circulation time to deliver PSs to target sites.
Moreover, self-quenchable nanoparticles formed by self-
aggregation of PS-polymer amphiphilies and PS-polymer
conjugate/quencher nanocomplexes have been proposed
as a more sophisticated strategy to modulate the photoac-
tivity PS. These PS-polymer conjugates-based formula-
tions can not only engage in solubilization and selective
accumulation but also can precisely control the photody-
namical reactions only occurring at tumor site, thereby,
maximizing the therapeutic efficacy and reducing the side
effects related to classic PDT. Although the most of
polymeric PS formulations are still undergoing testing
in experimental animal models or pre-clinical trials, the
above mentioned methodologies for PS delivery hold great
potential to bring PDT to the forefront of oncological
diseases treatment.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LL has made substantial contributions to the writing and editing all sections
of the manuscript. KMH has contributed significantly by reviewing and
suggesting changes overall the article, and has finally checked the
manuscript for grammatical and spelling mistakes. Both authors read and
approved the final manuscript.
Acknowledgments
This work was supported by the Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded by the Ministry of
Education, Science and Technology (2012R1A1A2005029 and
2013R1A2A2A04015914).
Received: 7 August 2014 Accepted: 2 October 2014
Published: 8 December 2014
References
1. Hamblin MR, Mróz P: Advances in Photodynamic Therapy : Basic,
Translational, and Clinical. Boston, Mass: Artech House; 2008.
2. Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S: Photodynamic
therapy of cancer. Basic principles and applications. Clin Transl Oncol Off
Publ Federation Spanish Oncol Soc National Cancer Institute Mexico 2008,
10:148–154.3. MacDonald IJ, Dougherty TJ: Basic principles of photodynamic therapy.
J Porphyr Phthalocya 2001, 5:105–129.
4. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan
J, Peng Q: Photodynamic therapy. J Natl Cancer Inst 1998, 90:889–905.
5. Zimcik P, Miletin M: Photodynamic therapy as a new prospective method
for cancer treatment. I. History, basic principles. Ceska Slovenska Farmacie
Casopis Ceske Farmaceuticke Spolecnosti Slovenske Farmaceuticke Spolecnosti
2004, 53:219–224.
6. Wilson BC: Photodynamic therapy for cancer: principles. Can J Gastroenterol J
Can Gastroenterol 2002, 16:393–396.
7. Dolmans DE, Fukumura D, Jain RK: Photodynamic therapy for cancer. Nat
Rev Cancer 2003, 3:380–387.
8. Sutedja TG, Postmus PE: Photodynamic therapy in lung cancer. A review.
J Photochem Photobiol B 1996, 36:199–204.
9. Senior K: Photodynamic therapy for bladder cancer. Lancet oncol 2005,
6:546.
10. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol
2010, 635:281–293.
11. Goff BA, Blake J, Bamberg MP, Hasan T: Treatment of ovarian cancer with
photodynamic therapy and immunoconjugates in a murine ovarian
cancer model. Br J Cancer 1996, 74:1194–1198.
12. Muschter R: Photodynamic therapy: a new approach to prostate cancer.
Current Urol Reports 2003, 4:221–228.
13. Roberts DJ, Cairnduff F: Photodynamic therapy of primary skin cancer: a
review. Br J Plast Surg 1995, 48:360–370.
14. Guleng GE, Helsing P: Photodynamic therapy for basal cell carcinomas in
organ-transplant recipients. Clin Exp Dermatol 2012, 37:367–369.
15. Konan YN, Gurny R, Allemann E: State of the art in the delivery of
photosensitizers for photodynamic therapy. J Photoch Photobio B 2002,
66:89–106.
16. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J: Direct tumor
damage mechanisms of photodynamic therapy. Acta Biochim Pol 2005,
52:339–352.
17. Milla Sanabria L, Rodriguez ME, Cogno IS, Rumie Vittar NB, Pansa MF,
Lamberti MJ, Rivarola VA: Direct and indirect photodynamic therapy
effects on the cellular and molecular components of the tumor
microenvironment. Biochim Biophys Acta 1835, 2013:36–45.
18. Krammer B: Vascular effects of photodynamic therapy. Anticancer Res
2001, 21:4271–4277.
19. Vancikova Z: Principles of the photodynamic therapy and its impact on
the immune system. Sb Lek 1998, 99:1–11.
20. Nowis D, Stoklosa T, Legat M, Issat T, Jakobisiak M, Golab J: The influence
of photodynamic therapy on the immune response. Photodiagnosis
Photodyn Ther 2005, 2:283–298.
21. Detty MR, Gibson SL, Wagner SJ: Current clinical and preclinical
photosensitizers for use in photodynamic therapy. J Med Chem 2004,
47:3897–3915.
22. O'Connor AE, Gallagher WM, Byrne AT: Porphyrin and nonporphyrin
photosensitizers in oncology: preclinical and clinical advances in
photodynamic therapy. Photochem Photobiol 2009, 85:1053–1074.
23. Ethirajan M, Chen Y, Joshi P, Pandey RK: The role of porphyrin chemistry in
tumor imaging and photodynamic therapy. Chem Soc Rev 2011, 40:340–362.
24. Daicoviciu D, Filip A, Ion RM, Clichici S, Decea N, Muresan A: Oxidative
photodamage induced by photodynamic therapy with methoxyphenyl
porphyrin derivatives in tumour-bearing rats. Folia Biol 2011, 57:12–19.
25. Pandey RK, Bellnier DA, Smith KM, Dougherty TJ: Chlorin and porphyrin
derivatives as potential photosensitizers in photodynamic therapy.
Photochem Photobiol 1991, 53:65–72.
26. Spikes JD: Phthalocyanines as photosensitizers in biological systems and
for the photodynamic therapy of tumors. Photochem Photobiol 1986,
43:691–699.
27. Moeno S, Krause RW, Ermilov EA, Kuzyniak W, Hopfner M: Synthesis and
characterization of novel zinc phthalocyanines as potential photosensitizers
for photodynamic therapy of cancers. Photochem Photobiol Sci 2014,
13:963–970.
28. Durmus M, Ahsen V: Water-soluble cationic gallium(III) and indium(III)
phthalocyanines for photodynamic therapy. J Inorg Biochem 2010,
104:297–309.
29. Kreimer-Birnbaum M: Modified porphyrins, chlorins, phthalocyanines, and
purpurins: second-generation photosensitizers for photodynamic
therapy. Semin Hematol 1989, 26:157–173.
Li and Huh Biomaterials Research 2014, 18:19 Page 13 of 14
http://www.biomaterialsres.com/content/18/1/1930. O'Neal WG, Roberts WP, Ghosh I, Wang H, Jacobi PA: Studies in chlorin
chemistry. 3. A practical synthesis of c, d-ring symmetric chlorins of
potential utility in photodynamic therapy. J Org Chem 2006,
71:3472–3480.
31. Vrouenraets MB, Visser GW, Snow GB, van Dongen GA: Basic principles,
applications in oncology and improved selectivity of photodynamic
therapy. Anticancer Res 2003, 23:505–522.
32. Liebmann J, Cook JA, Mitchell JB: Cremophor EL, solvent for paclitaxel,
and toxicity. Lancet 1993, 342:1428.
33. Gelderblom H, Verweij J, Nooter K, Sparreboom A: Cremophor EL: the
drawbacks and advantages of vehicle selection for drug formulation.
Eur J Cancer 2001, 37:1590–1598.
34. Derycke AS, de Witte PA: Liposomes for photodynamic therapy. Adv Drug
Deliv Rev 2004, 56:17–30.
35. Broekgaarden M, de Kroon AI, Gulik TM, Heger M: Development and
in vitro proof-of-concept of interstitially targeted zinc- phthalocyanine
liposomes for photodynamic therapy. Curr Med Chem 2013, 21:377–391.
36. Bovis MJ, Woodhams JH, Loizidou M, Scheglmann D, Bown SG, Macrobert
AJ: Improved in vivo delivery of m-THPC via pegylated liposomes for use
in photodynamic therapy. J Control Release 2012, 157:196–205.
37. Ricci-Junior E, Marchetti JM: Preparation, characterization,
photocytotoxicity assay of PLGA nanoparticles containing zinc (II)
phthalocyanine for photodynamic therapy use. J Microencapsul 2006,
23:523–538.
38. Ricci-Junior E, Marchetti JM: Zinc(II) phthalocyanine loaded PLGA
nanoparticles for photodynamic therapy use. Int J Pharm 2006,
310:187–195.
39. Chatterjee DK, Fong LS, Zhang Y: Nanoparticles in photodynamic therapy:
an emerging paradigm. Adv Drug Deliv Rev 2008, 60:1627–1637.
40. Lee YE, Kopelman R: Polymeric nanoparticles for photodynamic therapy.
Methods Mol Biol 2011, 726:151–178.
41. Chung CW, Chung KD, Jeong YI, Kang DH: 5-aminolevulinic acid-incorporated
nanoparticles of methoxy poly(ethylene glycol)-chitosan copolymer for
photodynamic therapy. Int J Nanomedicine 2013, 8:809–819.
42. Taillefer J, Brasseur N, van Lier JE, Lenaerts V, Le Garrec D, Leroux JC: In-vitro
and in-vivo evaluation of pH-responsive polymeric micelles in a photo-
dynamic cancer therapy model. J Pharmacy Pharmacol 2001, 53:155–166.
43. Gibot L, Lemelle A, Till U, Moukarzel B, Mingotaud AF, Pimienta V, Saint-Aguet
P, Rols MP, Gaucher M, Violleau F, Chassenieux C, Vicendo P: Polymeric
micelles encapsulating photosensitizer: structure/photodynamic therapy
efficiency relation. Biomacromolecules 2014, 15:1443–1455.
44. Koo H, Lee H, Lee S, Min KH, Kim MS, Lee DS, Choi Y, Kwon IC, Kim K, Jeong
SY: In vivo tumor diagnosis and photodynamic therapy via tumoral
pH-responsive polymeric micelles. Chem Commun (Camb) 2010,
46:5668–5670.
45. van Nostrum CF: Polymeric micelles to deliver photosensitizers for
photodynamic therapy. Adv Drug Deliv Rev 2004, 56:9–16.
46. Maeda H: The enhanced permeability and retention (EPR) effect in tumor
vasculature: the key role of tumor-selective macromolecular drug
targeting. Adv Enzyme Regul 2001, 41:189–207.
47. Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K: Nanomedicine
for drug targeting: strategies beyond the enhanced permeability and
retention effect. Int J Nanomedicine 2014, 9:2539–2555.
48. Li F, Bae BC, Na K: Acetylated hyaluronic acid/photosensitizer
conjugate for the preparation of nanogels with controllable
phototoxicity: synthesis, characterization, autophotoquenching
properties, and in vitro phototoxicity against HeLa cells. Bioconjug Chem
2010, 21:1312–1320.
49. Bae BC, Na K: Self-quenching polysaccharide-based nanogels of pullulan/
folate-photosensitizer conjugates for photodynamic therapy. Biomaterials
2010, 31:6325–6335.
50. Li L, Bae BC, Tran TH, Yoon KH, Na K, Huh KM: Self-quenchable
biofunctional nanoparticles of heparin-folate-photosensitizer conjugates
for photodynamic therapy. Carbohyd Polym 2011, 86:708–715.
51. Oh IH, Min HS, Li L, Tran TH, Lee YK, Kwon IC, Choi K, Kim K, Huh KM:
Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan
nanoparticles for photodynamic therapy in tumor-bearing mice.
Biomaterials 2013, 34:6454–6463.
52. Kim WL, Cho H, Li L, Kang HC, Huh KM: Biarmed poly(ethylene glycol)-
(pheophorbide a)2 conjugate as a bioactivatable delivery carrier for
photodynamic therapy. Biomacromolecules 2014, 15:2224–2234.53. Park W, Park SJ, Na K: The controlled photoactivity of nanoparticles
derived from ionic interactions between a water soluble polymeric
photosensitizer and polysaccharide quencher. Biomaterials 2011,
32:8261–8270.
54. Li L, Nurunnabi M, Nafiujjaman M, Lee YK, Huh KM: GSH-mediated
photoactivity of pheophorbide a-conjugated heparin/gold nanoparticle
for photodynamic therapy. J Control Release 2013, 171:241–250.
55. Li L, Md N, Md N, Jeong YY, Lee YK, Huh KM: A photosensitizer-conjugated
magnetic iron oxide/gold hybrid nanoparticle as an activatable platform
for photodynamic cancer therapy. J Mater Chem B 2014, 2:2929–2937.
56. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics
in cancer chemotherapy: mechanism of tumoritropic accumulation of
proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387–6392.
57. Maeda H, Matsumura Y: Tumoritropic and lymphotropic principles of
macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989, 6:193–210.
58. Ben-Dror S, Bronshtein I, Wiehe A, Roder B, Senge MO, Ehrenberg B: On the
correlation between hydrophobicity, liposome binding and cellular
uptake of porphyrin sensitizers. Photochem Photobiol 2006, 82:695–701.
59. Love WG, Duk S, Biolo R, Jori G, Taylor PW: Liposome-mediated delivery of
photosensitizers: localization of zinc (II)-phthalocyanine within implanted
tumors after intravenous administration. Photochem Photobiol 1996,
63:656–661.
60. Casas A, Batlle A: Aminolevulinic acid derivatives and liposome delivery
as strategies for improving 5-aminolevulinic acid-mediated photodynamic
therapy. Curr Med Chem 2006, 13:1157–1168.
61. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG: Liposomal
delivery of a photosensitizer, benzoporphyrin derivative monoacid ring
A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol
1993, 57:1000–1006.
62. Namiki Y, Namiki T, Date M, Yanagihara K, Yashiro M, Takahashi H:
Enhanced photodynamic antitumor effect on gastric cancer by a novel
photosensitive stealth liposome. Pharmacol Res Off J Ital Pharmacol Soc
2004, 50:65–76.
63. Sibani SA, McCarron PA, Woolfson AD, Donnelly RF: Photosensitiser
delivery for photodynamic therapy. Part 2: systemic carrier platforms.
Expert Opin Drug Deliv 2008, 5:1241–1254.
64. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC: Polymeric
nanoparticles for drug delivery. Methods Mol Biol 2010, 624:163–175.
65. Veronese FM, Pasut G: PEGylation, successful approach to drug delivery.
Drug Discov Today 2005, 10:1451–1458.
66. Jain A, Jain SK: PEGylation: an approach for drug delivery. A review.
Crit Rev Ther Drug Carrier Syst 2008, 25:403–447.
67. Kumari A, Yadav SK, Yadav SC: Biodegradable polymeric nanoparticles
based drug delivery systems. Colloids Surf B: Biointerfaces 2010, 75:1–18.
68. Allemann E, Brasseur N, Benrezzak O, Rousseau J, Kudrevich SV, Boyle RW,
Leroux JC, Gurny R, Van Lier JE: PEG-coated poly(lactic acid) nanoparticles
for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse
mammary tumours. J Pharmacy Pharmacol 1995, 47:382–387.
69. Konan YN, Berton M, Gurny R, Allemann E: Enhanced photodynamic
activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into
sub-200 nm nanoparticles. Eur J Pharm Sci 2003, 18:241–249.
70. Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allemann E: Preparation and
characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphy-
rin-loaded nanoparticles for photodynamic therapy. Eur J Pharm Biopharm Off
J Arbeitsgemeinschaft Pharm Verfahrenstechnik eV 2003, 55:115–124.
71. Aliabadi HM, Lavasanifar A: Polymeric micelles for drug delivery. Expert
Opin Drug Deliv 2006, 3:139–162.
72. Nishiyama N, Kataoka K: Current state, achievements, and future
prospects of polymeric micelles as nanocarriers for drug and gene
delivery. Pharmacol Ther 2006, 112:630–648.
73. Li B, Moriyama EH, Li F, Jarvi MT, Allen C, Wilson BC: Diblock copolymer
micelles deliver hydrophobic protoporphyrin IX for photodynamic
therapy. Photochem Photobiol 2007, 83:1505–1512.
74. Shieh MJ, Peng CL, Chiang WL, Wang CH, Hsu CY, Wang SJ, Lai PS:
Reduced skin photosensitivity with meta-tetra(hydroxyphenyl)chlorin-
loaded micelles based on a poly(2-ethyl-2-oxazoline)-b-poly(d, l-lactide)
diblock copolymer in vivo. Mol Pharm 2010, 7:1244–1253.
75. Knop K, Mingotaud AF, El-Akra N, Violleau F, Souchard JP: Monomeric
pheophorbide(a)-containing poly(ethyleneglycol-b-epsilon-caprolactone)
micelles for photodynamic therapy. Photochem Photobiol Sci 2009,
8:396–404.
Li and Huh Biomaterials Research 2014, 18:19 Page 14 of 14
http://www.biomaterialsres.com/content/18/1/1976. Li L, Cho H, Yoon KH, Kang HC, Huh KM: Antioxidant-photosensitizer
dual-loaded polymeric micelles with controllable production of reactive
oxygen species. Int J Pharm 2014, 471:339–348.
77. Muthiah M, Park SH, Nurunnabi M, Lee J, Lee YK, Park H, Lee BI, Min JJ, Park
IK: Intracellular delivery and activation of the genetically encoded
photosensitizer Killer Red by quantum dots encapsulated in polymeric
micelles. Colloid Surface B Biointerfaces 2014, 116:284–294.
78. Bulina ME, Chudakov DM, Britanova OV, Yanushevich YG, Staroverov DB,
Chepurnykh TV, Merzlyak EM, Shkrob MA, Lukyanov S, Lukyanov KA: A
genetically encoded photosensitizer. Nat Biotechnol 2006, 24:95–99.
79. Liao ZX, Li YC, Lu HM, Sung HW: A genetically-encoded KillerRed protein
as an intrinsically generated photosensitizer for photodynamic therapy.
Biomaterials 2014, 35:500–508.
80. Pletnev S, Gurskaya NG, Pletneva NV, Lukyanov KA, Chudakov DM, Martynov
VI, Popov VO, Kovalchuk MV, Wlodawer A, Dauter Z, Pletnev V: Structural
basis for phototoxicity of the genetically encoded photosensitizer
KillerRed. J Biol Chem 2009, 284:32028–32039.
81. Ryumina AP, Serebrovskaya EO, Shirmanova MV, Snopova LB, Kuznetsova
MM, Turchin IV, Ignatova NI, Klementieva NV, Fradkov AF, Shakhov BE,
Zagaynova EV, Lukyanov KA, Lukyanov SA: Flavoprotein miniSOG as a
genetically encoded photosensitizer for cancer cells. Biochim Biophys Acta
1830, 2013:5059–5067.
82. Verhille M, Couleaud P, Vanderesse R, Brault D, Barberi-Heyob M, Frochot C:
Modulation of photosensitization processes for an improved targeted
photodynamic therapy. Curr Med Chem 2010, 17:3925–3943.
83. Lovell JF, Liu TWB, Chen J, Zheng G: Activatable Photosensitizers for
Imaging and Therapy. Chem Rev 2010, 110:2839–2857.
84. Bugaj AM: Targeted photodynamic therapy–a promising strategy of
tumor treatment. Photochem Photobiol Sci 2011, 10:1097–1109.
85. McCarthy JR, Weissleder R: Model systems for fluorescence and singlet
oxygen quenching by metalloporphyrins. ChemMedChem 2007,
2:360–365.
86. Lovell JF, Chen J, Jarvi MT, Cao WG, Allen AD, Liu Y, Tidwell TT, Wilson BC,
Zheng G: FRET quenching of photosensitizer singlet oxygen generation.
J Phys Chem B 2009, 113:3203–3211.
87. Lee SJ, Koo H, Lee DE, Min S, Lee S, Chen X, Choi Y, Leary JF, Park K, Jeong
SY, Kwon IC, Kim K, Choi K: Tumor-homing photosensitizer-conjugated
glycol chitosan nanoparticles for synchronous photodynamic imaging
and therapy based on cellular on/off system. Biomaterials 2011,
32:4021–4029.
88. Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM: Glutathione levels in
human tumors. Biomarkers 2012, 17:671–691.
doi:10.1186/2055-7124-18-19
Cite this article as: Li and Huh: Polymeric nanocarrier systems for
photodynamic therapy. Biomaterials Research 2014 18:19.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
